To investigate whether serum biomarkers can be used to indicate the responsiveness of acute myeloid leukemia (AML) to remission induction chemotherapy, we performed MALDI-TOF protein profile analysis of patient sera. The resulting spectra revealed a protein (or peptide) peak at m/z 7764 that varied in intensity; its intensity was much higher in samples from patients in complete remission than in those from patients with resistant disease, or in samples taken prior to treatment (at the time of diagnosis). Using fractionation, trypsin digestion, and MS/MS and protein molecular weight analyses, we identified the m/z 7764 protein as platelet factor-4 (PF4). This identification was confirmed by a magnetic bead-based MALDI immunoassay. Statistical comparison of PF4 levels and platelet counts in patient sera revealed a significant positive correlation between the two variables. This study demonstrates that PF4 protein levels are a good indicator for the recovery of blood count in the complete remission of AML. The linear positive correlation curve indicates that blood count recovery of platelets to >100,000/mm3 is equivalent to a serum PF4 recovery level of >2.492 µg/mL.